Beximco Pharmaceuticals Ltd Payment of Cash Dividend (1847N)
January 19 2023 - 2:00AM
UK Regulatory
TIDMBXP
RNS Number : 1847N
Beximco Pharmaceuticals Ltd
19 January 2023
19 January 2023
BEXIMCO PHARMACEUTICALS LIMITED
Payment of Cash Dividend
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces that the 35%
cash dividend of the nominal value per ordinary share/GDR (Taka
3.50 per ordinary share/GDR) for the year ended 30 June 2022, which
was approved in the Annual General Meeting ("AGM") held on 22
December 2022, has been deposited with the custodian bank in Dhaka
on 18 January 2023 for onward credit to respective GDR holders'
accounts.
For any queries regarding the credit of dividend to respective
accounts of holders of GDRs, please contact the Depository (The
Bank of New York Mellon) representative, Mr. Vinu Kurian, at
vinu.kurian@bnymellon.com .
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext. 20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebulizer solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5,500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DIVNKFBNOBKDCDD
(END) Dow Jones Newswires
January 19, 2023 02:00 ET (07:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2024 to Jun 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Jun 2023 to Jun 2024